|Title:||Methods for treating urticaria using descarboethoxyloratadine|
|Abstract:||Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.|
|Inventor(s):|| Aberg; A. K. Gunnar (Westborough, MA), McCullough; John R. (Worcester, MA), Smith; Emil R. (Shrewsbury, MA) |
|Assignee:|| Sepracor Inc. (Marlborough, MA) |
1. A method of treating urticaria in a human comprising orally administering to a human a therapeutically effective amount of descarboethoxyloratadine (DCL) or a
pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is from 0.1 to 5.0 mg per day.
2. The method of claim 1 wherein the amount of said descarboethoxyloratadine (DCL) is administered together with a pharmaceutically acceptable carrier.